IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. Nat Commun. 2022 10 03; 13(1):5814.
View in:
PubMed
Immune Evasion of SARS-CoV-2 Omicron Subvariants. Vaccines (Basel). 2022 Sep 16; 10(9).
View in:
PubMed
Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells. Int J Mol Sci. 2022 May 13; 23(10).
View in:
PubMed
Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants. EBioMedicine. 2022 Jun; 80:104025.
View in:
PubMed
Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y. J Virol. 2022 03 23; 96(6):e0198221.
View in:
PubMed
Anti-CAIX BB? CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model. Mol Ther Oncolytics. 2022 Mar 17; 24:385-399.
View in:
PubMed
Unique structural solution from a VH3-30 antibody targeting the hemagglutinin stem of influenza A viruses. Nat Commun. 2021 01 25; 12(1):559.
View in:
PubMed
Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease. Clin Chem. 2020 12 01; 66(12):1562-1572.
View in:
PubMed
High-Throughput Image Cytometry Detection Method for CAR-T Transduction, Cell Proliferation, and Cytotoxicity Assays. Cytometry A. 2021 07; 99(7):689-697.
View in:
PubMed
A Novel Framework for Characterizing Genomic Haplotype Diversity in the Human Immunoglobulin Heavy Chain Locus. Front Immunol. 2020; 11:2136.
View in:
PubMed
Author Correction: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2020 Jul; 26(7):1146.
View in:
PubMed
A New Humanized Mouse Model Mimics Humans in Lacking a-Gal Epitopes and Secreting Anti-Gal Antibodies. J Immunol. 2020 04 01; 204(7):1998-2005.
View in:
PubMed
A high-throughput chemotaxis detection method for CCR4+ T cell migration inhibition using image cytometry. J Immunol Methods. 2020 04; 479:112747.
View in:
PubMed
Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody. J Virol. 2019 01 15; 93(2).
View in:
PubMed
Alcohol consumption increases susceptibility to pneumococcal pneumonia in a humanized murine HIV model mediated by intestinal dysbiosis. Alcohol. 2019 11; 80:33-43.
View in:
PubMed
Synonymous Mutations at the Beginning of the Influenza A Virus Hemagglutinin Gene Impact Experimental Fitness. J Mol Biol. 2018 04 13; 430(8):1098-1115.
View in:
PubMed
The latest animal models of ovarian cancer for novel drug discovery. Expert Opin Drug Discov. 2018 03; 13(3):249-257.
View in:
PubMed
Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope. Cell Rep. 2017 Dec 12; 21(11):3243-3255.
View in:
PubMed
Immunocapture isotope dilution mass spectrometry in response to a pandemic influenza threat. Vaccine. 2017 09 05; 35(37):5011-5018.
View in:
PubMed
The Individual and Population Genetics of Antibody Immunity. Trends Immunol. 2017 07; 38(7):459-470.
View in:
PubMed
A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol. 2016 Nov 28; 2:16226.
View in:
PubMed
Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates. Am J Trop Med Hyg. 2016 Nov 02; 95(5):1148-1156.
View in:
PubMed
A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve. Nat Commun. 2016 09 13; 7:12780.
View in:
PubMed
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016 Jun 07; 7(23):34341-55.
View in:
PubMed
Erratum: IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Sci Rep. 2016 04 29; 6:23876.
View in:
PubMed
Corrigendum: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2016 Apr; 22(4):446.
View in:
PubMed
SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A. 2016 Mar 15; 113(11):3048-53.
View in:
PubMed
Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. MAbs. 2016 May-Jun; 8(4):787-98.
View in:
PubMed
IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Sci Rep. 2016 Feb 16; 6:20842.
View in:
PubMed
3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology. 2016 03; 490:49-58.
View in:
PubMed
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016 Mar; 5(3):e1090075.
View in:
PubMed
A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015 Dec; 21(12):1508-13.
View in:
PubMed
Reconstitution of the receptor-binding motif of the SARS coronavirus. Protein Eng Des Sel. 2015 Dec; 28(12):567-75.
View in:
PubMed
Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy. Immunotherapy. 2015; 7(6):591-4.
View in:
PubMed
Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Mol Cancer. 2015 Jun 11; 14:119.
View in:
PubMed
Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme. J Virol. 2015 Jul; 89(14):7202-13.
View in:
PubMed
Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. Blood. 2015 Jun 18; 125(25):3886-95.
View in:
PubMed
Phage and Yeast Display. Microbiol Spectr. 2015 Feb; 3(1):AID-0028-2014.
View in:
PubMed
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor. Mol Ther Oncolytics. 2014; 1:14003.
View in:
PubMed
Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages. J Neuroinflammation. 2014 Nov 22; 11:195.
View in:
PubMed
Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J Virol. 2014 Dec; 88(23):13769-80.
View in:
PubMed
Prolonged expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital tract by AAV gene transfer. Gene Ther. 2014 Sep; 21(9):802-10.
View in:
PubMed
Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog. 2014 May; 10(5):e1004103.
View in:
PubMed
Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A. 2014 May 13; 111(19):E2018-26.
View in:
PubMed
Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. MAbs. 2014 May-Jun; 6(3):577-618.
View in:
PubMed
Identification and isolation of small CD44-negative mesenchymal stem/progenitor cells from human bone marrow using elutriation and polychromatic flow cytometry. Stem Cells Transl Med. 2013 Aug; 2(8):567-78.
View in:
PubMed
Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. FASEB J. 2013 Feb; 27(2):581-9.
View in:
PubMed
Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PLoS One. 2012; 7(9):e44455.
View in:
PubMed
In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat. Hum Gene Ther. 2012 Sep; 23(9):917-31.
View in:
PubMed
Fatal fulminant hepatic failure from adenovirus in allogeneic bone marrow transplant patients. Case Rep Infect Dis. 2012; 2012:463569.
View in:
PubMed
Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther. 2012 Nov; 11(11):2451-61.
View in:
PubMed
Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods. J Clin Microbiol. 2012 Oct; 50(10):3216-21.
View in:
PubMed
Human B-cell ontogeny in humanized NOD/SCID ?c(null) mice generates a diverse yet auto/poly- and HIV-1-reactive antibody repertoire. Genes Immun. 2012 Jul; 13(5):399-410.
View in:
PubMed
Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cells. Immunology. 2011 Dec; 134(4):419-33.
View in:
PubMed
Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One. 2011; 6(10):e26473.
View in:
PubMed
Fine epitope mapping of monoclonal antibodies against hemagglutinin of a highly pathogenic H5N1 influenza virus using yeast surface display. Biochem Biophys Res Commun. 2011 Jun 03; 409(2):253-9.
View in:
PubMed
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis. 2011 Apr 15; 52(8):1003-9.
View in:
PubMed
Structural basis of influenza virus neutralization. Ann N Y Acad Sci. 2011 Jan; 1217:178-90.
View in:
PubMed
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011 Jan 17; 208(1):181-93.
View in:
PubMed
Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem Biophys Res Commun. 2010 Dec 10; 403(2):247-51.
View in:
PubMed
Antibodies and lentiviruses that specifically recognize a T cell epitope derived from HIV-1 Nef protein and presented by HLA-C. J Immunol. 2010 Dec 15; 185(12):7623-32.
View in:
PubMed
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer. 2010 Aug 01; 127(3):598-611.
View in:
PubMed
Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One. 2010 Mar 10; 5(3):e9625.
View in:
PubMed
Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2010 Mar; 5(1):81-93.
View in:
PubMed
Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol. 2009 Jul 01; 183(1):650-60.
View in:
PubMed
Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Hum Gene Ther. 2009 Jun; 20(6):554-62.
View in:
PubMed
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009 Mar; 16(3):265-73.
View in:
PubMed
Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. J Leukoc Biol. 2009 Jan; 85(1):165-74.
View in:
PubMed
Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog. 2008 Nov; 4(11):e1000197.
View in:
PubMed
Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles. PLoS One. 2008 Sep 11; 3(9):e3181.
View in:
PubMed
Influenza A virus neuraminidase limits viral superinfection. J Virol. 2008 May; 82(10):4834-43.
View in:
PubMed
The Collection, Processing and Storage of Adult Stem Cells – A Bio-Insurance Policy for Personalized Medical Therapies. Life Extension Foundation magazine. 2008.
Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol. 2008; (181):343-73.
View in:
PubMed
The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007 Dec; 25(12):1421-34.
View in:
PubMed
Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-region sulfation, and define CXCR4 antigenic heterogeneity. J Immunol. 2007 Aug 15; 179(4):2408-18.
View in:
PubMed
The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology. 2007 Oct 25; 367(2):367-74.
View in:
PubMed
Negative regulation of the SH2-homology containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 Tax oncoprotein. Blood. 2007 Sep 15; 110(6):2110-20.
View in:
PubMed
Intracellular antibodies (Intrabodies) as specific molecules for therapeutic applications. In Handbook of Experimental Pharmacology. Chernajovsky Y, ed. 2007.
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem. 2006 Nov 10; 281(45):34610-6.
View in:
PubMed
Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol. 2006 Nov; 80(22):11000-8.
View in:
PubMed
Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun. 2006 Oct 06; 348(4):1245-53.
View in:
PubMed
Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther. 2006 Aug; 5(8):2096-105.
View in:
PubMed
Convergent Combination Immunotherapy for the Prevention and Treatment of SARS. The 5th International Congress on Recombinant Antibodies. Zurich, Switzerland. 2006.
Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci U S A. 2006 May 09; 103(19):7454-9.
View in:
PubMed
Passive immunotherapy in an outbreak setting. A case of SARS. From Concept to Clinic. Cambridge Health Institute’s 7th Annual Meeting, Boston, MA. 2006.
Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. J Mol Biol. 2006 May 26; 359(1):190-201.
View in:
PubMed
Immunopathogenesis and Immunotherapy of SARS. In Challenges of Severe Acute Respiratory Syndrome. Chan JCK and Wong VCW, eds. 2006.
Human neutralizing antibodies for convergent immunotherapy against SARS. 16th Annual International Conference on Antibody Engineering, San Diego, CA. 2005.
Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol. 2005 Dec; 79(23):14606-13.
View in:
PubMed
A strategy to move potent neutralizing anti-SARS monoclonal antibodies into clinical trials in an outbreak setting. The Second China International Symposium on Antibody Engineering. Invited Speaker. Therapeutic Antibodies for Non-Malignant Diseases. Beijing, China,. 2005.
A Strategy Toward Convergent Combination Immunotherapy for SARS. ICLAS-CALAS International Symposium. Animal Models of Infectious Diseases. Beijing, China. 2005.
Development of Renal Cell Carcinoma (RCC) Vaccine against G250 by Co-Expression of G250 Extracellular Domain-Fc Fusion Protein and IL-2 Using 2A Self-Processing Peptide. CHI Conference. Cancer Immunotheerptics and Targeted Cancer Therapies, Boston, MA. 2005.
Role of HTLV-1 Tax in SH2-containing Tyrosine Phosphatase-1 (SHP-1) Promoter Silencing in Acute Infection and Adult T-Cell Leukemia. 12th International Conference on Human Retrovirology: HTLV-1 and Related Viruses. Montego Bay, Jamaica. 2005.
Suppresses Shp-1 (SH2-containing Tyrosine Phosphatase-1) Gene Expression and Facilitates Leukemogenesis Through Tax-Promoter Interaction. 12th International Conference on Human Retrovirology: HTLV-1 and Related Viruses. Montego Bay, Jamaica. 2005.
An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol. 2005 Jul; 206(3):251-9.
View in:
PubMed
GITR overexpression on CD4+CD25+ HTLV-1 transformed cells: detection by massively parallel signature sequencing. Biochem Biophys Res Commun. 2005 Jul 01; 332(2):569-84.
View in:
PubMed
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005 Jun; 23(6):709-17.
View in:
PubMed
Therapeutic antibody gene transfer. Nat Biotechnol. 2005 May; 23(5):551-2.
View in:
PubMed
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol. 2005 May; 79(10):5900-6.
View in:
PubMed
Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005 Apr 20; 24(8):1634-43.
View in:
PubMed
Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005 Mar 15; 65(6):2344-52.
View in:
PubMed
Role of SHP-1 deregulation in HTLV-1 leukemogenesis. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. 2005.
Potential Use of Human Monoclonal Antibodies Against CXCR4 for the Prevention and Treatment of Breast Cancer Metastasis. Keystone Symposium on Antibody Based Therapeutics for Cancer, Santa Fe, NM. 2005.
T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther. 2005 Feb; 12(4):299-310.
View in:
PubMed
A strategy for Global Collaborations to Develop Human Monoclonal Antibody (mAb) Drugs for the Treatment of Cancer. Oncology Research. 2005; 15:458.
Preventive and therapeutic immunization against lethal murine West Nile virus infection with a bivalent human single-chain antibody (scFv)-Fc fusion protein and rabbit polyclonal antibody against the envelope protein. American Association of Tropical Medicine and Hygiene Annual Meeting, Miami Beach, FL. 2004.
Targeting Dendritic Cells: Selection of Single Chain Antibodies from a Human Phage Display Library. The 12th Annual Congress of the European Society of Gene Therapy, Tampere, Finland. 2004.
MHC class I manipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies--a tool for decreased immunogenicity of allogeneic tissue and cell transplants. Methods. 2004 Oct; 34(2):240-9.
View in:
PubMed
Isolation of human antibodies against CXCR4 by paramagnetic proteoliposomes for prevention and treatment of breast cancer metastases. The Susan G, Komen Cancer Foundation Pathways to a Promise. New York, NY. 2004.
Transcriptional deregulation in adult T-cell leukemia: Genome-wide transcriptional profiling of acutely HTLV-1 transformed cells using Massively Parallel Signature Sequencing. 95th AACR Annual Meeting, Orlando, FL. 2004.
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A. 2004 Feb 24; 101(8):2536-41.
View in:
PubMed
Abrogation of Fibroblast Activation Protein Enzymatic Activity Attenuates Tumor Growth. AACR Annual Meeting, Dana Point, CA. 2004.
Role of SHP-1 deregulation in HTLV-1 leukemogenesis. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. 2004.
Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. J Mol Biol. 2004 Jan 02; 335(1):193-207.
View in:
PubMed
Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells. Leuk Res. 2004 Jan; 28(1):71-82.
View in:
PubMed
Identification of CD4 and transferrin receptor antibodies by CXCR4 antibody-guided Pathfinder selection. Eur J Biochem. 2003 Nov; 270(22):4497-506.
View in:
PubMed
Fatal Fulminant Hepatic Failure from Adenovirus in Allogeneic Bone Marrow Transplant Patients. 41st Annual Meeting of Infectious Diseases Society of America. 2003.
Breakthrough Zygomycosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients Who Received Voriconazole as Prophylaxis or Empiric Therapy. 43rd ICAAC. 2003.
Down-Regulation of SHP1 and Up-Regulation of Negative Regulators of JAK/STAT Signaling in HTLV-1 Transformed Cell Lines and Freshly Transformed Human Peripheral Blood CD4+ T-cells. 3rd Annual Harvard Medical School Centers for AIDS Research Symposium, Boston, MA. 2003.
Generation and Characterization of Engineered Human Anti-CCR5 Antibodies. 3rd Annual Harvard Medical School Centers for AIDS Research Symposium, Boston, MA. 2003.
Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies. J Acquir Immune Defic Syndr. 2003 Mar 01; 32(3):245-54.
View in:
PubMed
Intrabodies as Tools to Perturb Cellular Function. Guest Speaker for the Antibody-Based Therapeutics for Cancer, 2003 Keystone Symposia. 2003.
Intracellular targeting of antibodies in mammalian cells. In New Comprehensive Biocehmistry : Gene Transfer and Expression in Mammalian Cells. Savvas C. Makrides , ed. 2003; 573 – 623.
Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology. 2002 Nov 10; 303(1):9-14.
View in:
PubMed
Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem. 2003 Jan 17; 278(3):1433-42.
View in:
PubMed
Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther. 2002 Mar; 9(5):307-19.
View in:
PubMed
Hiv-1 Tat can substantially enhance the capacity of NIK to induce IkappaB degradation. Biochem Biophys Res Commun. 2001 Aug 24; 286(3):587-94.
View in:
PubMed
Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther. 2001 Aug; 8(8):555-65.
View in:
PubMed
Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector. Mol Med. 2001 Aug; 7(8):569-79.
View in:
PubMed
Intrabodies as antiviral agents. Curr Top Microbiol Immunol. 2001; 260:247-70.
View in:
PubMed
Intrabodies as anti-viral agents. In Current Topics in Microbiology and Immunology. Dennis R. Burton,ed. 2001; 260:247-70.
Expression vectors and methods of use. 2000.
Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc. J Biol Chem. 2000 Oct 06; 275(40):30925-33.
View in:
PubMed
Upregulation of the apoptosis-associated protein Grb3-3 in HIV-1-infected human CD4(+) lymphocytes. Biochem Biophys Res Commun. 2000 Sep 16; 276(1):362-70.
View in:
PubMed
Method of intracellular binding of target molecules. 2000.
Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol. 2000 Jun; 18(6):649-54.
View in:
PubMed
Rapid establishment of myeloma cell lines expressing Fab (Tac)-Protamine, A targetable protein vector, directed against the high affinity alpha chain of the human interleukin-2 receptor. In Methods in Molecular Biology. Eric Kmiec, ed. 2000; 133:156-66.
Rapid establishment of myeloma cell lines expressing Fab(Tac)-protamine, a targetable protein vector, directed against high-affinity alpha-chain of human interleukin-2 receptor. Methods Mol Biol. 2000; 133:157-66.
View in:
PubMed
Intracellular targeting of endogenous proteins. 1999.
Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Methods. 1999 Dec 10; 231(1-2):223-38.
View in:
PubMed
Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J Immunol Methods. 1999 Dec 10; 231(1-2):207-22.
View in:
PubMed
Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat. Hum Gene Ther. 1999 Oct 10; 10(15):2505-14.
View in:
PubMed
Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Hum Gene Ther. 1999 Jun 10; 10(9):1453-67.
View in:
PubMed
Reactive neutralizing human anti-gp120 recombinant antibody, DNA coding the same and use thereof. 1998.
Method of intracellular binding of target molecules. 1998.
Method of intracellular binding of target molecules. 1998.
Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Hum Gene Ther. 1998 Jul 20; 9(11):1627-42.
View in:
PubMed
Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene Ther. 1998 May; 5(5):635-44.
View in:
PubMed
Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. Adv Drug Deliv Rev. 1998 Apr 06; 31(1-2):153-170.
View in:
PubMed
The therapeutic potential of intracellular antibodies. BioDrugs. 1998 Mar; 9(3):179-85.
View in:
PubMed
Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum Gene Ther. 1998 Mar 01; 9(4):487-96.
View in:
PubMed
Localization of HIV-1 co-receptors CCR5 and CXCR4 in the brain of children with AIDS. Am J Pathol. 1998 Jan; 152(1):167-78.
View in:
PubMed
Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. In Advanced Drug Reviews. 1998; 31:153-170.
Inducible knockout of the interleukin-2 receptor alpha chain: expression of the high-affinity IL-2 receptor is not required for the in vitro growth of HTLV-I-transformed cell lines. Virology. 1997 Oct 27; 237(2):209-16.
View in:
PubMed
Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists. J Virol. 1997 Sep; 71(9):6486-94.
View in:
PubMed
Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Mol Med. 1997 Feb; 3(2):96-110.
View in:
PubMed
Intrabodies targeted against regulatory epitopes of HIV-1: Tat and Rev as two significant targets for gene therapy. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997.
Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther. 1997 Jan; 4(1):11-5.
View in:
PubMed
Studies on the phenotypic ¡§knockout¡¨ of the human interleukin-2 receptor ƒÑ chain. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997.
Designing Intrabodies: Structural features and the use of intracellular trafficking signals. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997.
Intrabodies: From antibody genes to intracellular immunization. In The Antibodies, Zanetti M and Capra JD, eds. 1997; 4.
Gene therapy for HIV-1 using intracellular antibodies against HIV-1 Gag proteins. In Intrabodies: Basic Research and Clinical Gene Therapy Applications. Molecular Biology Intelligence Unit. Marasco WA, ed. 1997.
The therapeutic potential of intracellular antibodies. In BioDrugs. Beedle AS, ed. 1997.
Intracellular antibodies (intrabodies): Potential applications in transgenic animal research and engineered resistance to pathogens. In Transgenic Animals - Generation and Use. Houdebine L-M, ed.
. 1997; 74:501-6.
Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol. 1997; 51:257-83.
View in:
PubMed
Intra- and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody. Hum Gene Ther. 1996 Aug 20; 7(13):1515-25.
View in:
PubMed
Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Semin Oncol. 1996 Feb; 23(1):148-53.
View in:
PubMed
Intrabody-based gene therapy approaches against HIV-1. In -Advancing a New Agenda for AIDS Research, Poznansky M.C., Coker R.J. and Gilles P., eds. 1996.
Gene Therapy and Research Applications of Intrabodies for Human Infectious Diseases. In The Use of Ectopic Antibody Expression for Intracellular and Extracellular Immunization. Biocca S. And Cattaneo A., eds. 1996.
Looking ahead: Combination of intracellular single-chain antibodies and other genetic-based anti-HIV-1 approaches hold promise as an effective strategy for AIDS gene therapy. In Drugs, News and Perspectives. 1996; 9:220-7.
Intracellular antibodies: development and therapeutic potential. Trends Biotechnol. 1995 Aug; 13(8):306-10.
View in:
PubMed
Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology. 1995 May; 1(1):1-19.
View in:
PubMed
Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci U S A. 1995 Apr 11; 92(8):3137-41.
View in:
PubMed
Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 1995 Apr 03; 14(7):1542-51.
View in:
PubMed
Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther. 1995 Mar; 2(2):116-23.
View in:
PubMed
Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. J Clin Invest. 1995 Feb; 95(2):732-7.
View in:
PubMed
Gene therapy. In HIV: A Practical Approach: Volume 2, Biochemistry, Molecular Biology, Drug Discovery. Karn J, ed. 1995.
Intracellular antibodies for HIV-1 gene therapy. In Expert Opinion on Investigational Drugs. 1995; 4:823-31.
Chemotaxis and activation of neutrophils. In Symposium on Chemical Mediators of Inflammation. Japan, Cohen S, Hayashi H, Saito K, and Takada A. eds. 1995; 220-4.
Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120. Mol Immunol. 1994 Oct; 31(15):1149-60.
View in:
PubMed
Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci U S A. 1994 Jun 21; 91(13):5932-6.
View in:
PubMed
Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther. 1994 May; 5(5):595-601.
View in:
PubMed
Spatial association of HIV-1 tat protein and the nucleolar transport protein B23 in stably transfected Jurkat T-cells. Arch Virol. 1994; 139(1-2):133-54.
View in:
PubMed
Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci U S A. 1993 Aug 15; 90(16):7889-93.
View in:
PubMed
Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. J Clin Invest. 1992 Oct; 90(4):1467-78.
View in:
PubMed
Acquired immunodeficiency syndrome with disseminated toxoplasmosis presenting as an acute pulmonary and gastrointestinal illness. Arch Pathol Lab Med. 1991 May; 115(5):459-63.
View in:
PubMed
Group C streptococcal bacteremia: analysis of 88 cases. Rev Infect Dis. 1991 Mar-Apr; 13(2):270-80.
View in:
PubMed
Characterization of a class of nonformylated Enterococcus faecalis-derived neutrophil chemotactic peptides: the sex pheromones. Proc Natl Acad Sci U S A. 1990 Jan; 87(1):66-70.
View in:
PubMed
Unusual presentation of cat scratch disease in a patient positive for antibody to the human immunodeficiency virus. Rev Infect Dis. 1989 Sep-Oct; 11(5):793-803.
View in:
PubMed
Autoradiographic analysis of formylpeptide chemoattractant binding, uptake and intracellular processing by neutrophils. J Cell Sci. 1989 Sep; 94 ( Pt 1):155-68.
View in:
PubMed
Regulation of formyl peptide receptor binding to rabbit neutrophil plasma membranes. Use of monovalent cations, guanine nucleotides, and bacterial toxins to discriminate among different states of the receptor. J Immunol. 1989 Jun 01; 142(11):3963-70.
View in:
PubMed
Recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) regulates f Met-Leu-Phe receptors on human neutrophils. Immunology. 1988 Jul; 64(3):519-25.
View in:
PubMed
Recombinant human tumor necrosis factor-alpha. Regulation of N-formylmethionylleucylphenylalanine receptor affinity and function on human neutrophils. J Clin Invest. 1988 Mar; 81(3):759-65.
View in:
PubMed
Chemotactic factors of bacterial origin. Methods Enzymol. 1988; 162:198-214.
View in:
PubMed
Chemotactic factors of bacterial origin. Chapter 19. In Immunological Techniques. Part L. Chemotaxis and Inflammation. Methods in Enzymology. DiSabato G, Langone JJ, and VanVunakis H, eds. 1988; Vol. 162:198-214.
Ibuprofen-associated renal dysfunction. Pathophysiologic mechanisms of acute renal failure, hyperkalemia, tubular necrosis, and proteinuria. Arch Intern Med. 1987 Dec; 147(12):2107-16.
View in:
PubMed
Direct visualization of formylpeptide receptor binding on rounded and polarized human neutrophils: cellular and receptor heterogeneity. J Leukoc Biol. 1987 May; 41(5):377-91.
View in:
PubMed
Heterogeneity and topographical asymmetry of formyl peptide receptor binding on polymorphonuclear leukocytes. In The Biology of Phagocytes in Health and Disease. Mauri C, Rizzo SC, and Ricevuti G, eds. 1987; 9-21.
Characterization of the plasma membrane bound GTPase from rabbit neutrophils. I. Evidence for an Ni-like protein coupled to the formyl peptide, C5a, and leukotriene B4 chemotaxis receptors. J Immunol. 1986 Sep 15; 137(6):1961-70.
View in:
PubMed
Inhibition of neutrophil activation by p-bromophenacyl bromide and its effects on phospholipase A2. Br J Pharmacol. 1986 Jun; 88(2):463-72.
View in:
PubMed
Covalent affinity labeling, detergent solubilization, and fluid-phase characterization of the rabbit neutrophil formyl peptide chemotaxis receptor. Biochemistry. 1985 Apr 23; 24(9):2227-36.
View in:
PubMed
Chemotactic factor binding by metastatic tumour cells: evidence for a formyl-peptide receptor on a non-myelogenous cell. J Cell Sci. 1985 Feb; 73:121-34.
View in:
PubMed
A search for "Internal Image" anti-idiotypic antibodies: A subpopulation of anti-f Met-Leu-Phe anti-idiotypic antibodies binds to the formyl peptide chemotaxis receptor of the neutrophil and to several genetically unrelated anti-f Met-Leu-Phe antibodies. In UCLA Symposium on Molecular and Cellular Biology. New Series, Reisfeld RA and Sell S. eds. 1985; 27:327-44.
Formyl peptide chemotaxis receptors on the rat neutrophil: experimental evidence for negative cooperativity. J Cell Biochem. 1985; 27(4):359-75.
View in:
PubMed
What are the molecular characteristics of the neutrophil receptor for chemotactic formylated peptides? Surv Immunol Res. 1985; 4(3):213-9.
View in:
PubMed
Localization of chemotactic peptide receptors on rabbit neutrophils. Exp Cell Res. 1984 Oct; 154(2):613-8.
View in:
PubMed
Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem. 1984 May 10; 259(9):5430-9.
View in:
PubMed
Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. Am J Pathol. 1984 Apr; 115(1):9-16.
View in:
PubMed
A specific enzyme-linked immunosorbent assay (ELISA) for the determination of human C5a antigen. J Immunol Methods. 1983 Sep 16; 62(3):305-14.
View in:
PubMed
Characterization of the rat neutrophil formyl peptide chemotaxis receptor. Am J Pathol. 1983 Jun; 111(3):273-81.
View in:
PubMed
Anti-inflammatory effects of prostaglandin E1: in vivo modulation of the formyl peptide chemotactic receptor on the rat neutrophil. J Immunol. 1983 Apr; 130(4):1495-7.
View in:
PubMed
Spasmogenic activity of chemotactic N-formylated oligopeptides: identity of structure--function relationships for chemotactic and spasmogenic activities. Proc Natl Acad Sci U S A. 1982 Dec; 79(23):7470-3.
View in:
PubMed
Anti-idiotype as antibody against the formyl peptide chemotaxis receptor of the neutrophil. J Immunol. 1982 Feb; 128(2):963-8.
View in:
PubMed
Anti-f Met-Leu-Phe: similarities in fine specificity with the formyl peptide chemotaxis receptor of the neutrophil. J Immunol. 1982 Feb; 128(2):956-62.
View in:
PubMed
Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil. Biochem Biophys Res Commun. 1981 Apr 30; 99(4):1065-72.
View in:
PubMed
The ionic basis of chemotaxis. Separate cation requirements for neutrophil orientation and locomotion in a gradient of chemotactic peptide. Am J Pathol. 1980 Mar; 98(3):749-68.
View in:
PubMed